SCHEMBL1847644

SCHEMBL1847644

CCC(C)(O)NCc1ccccc1

nearest known ligand 0.61

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RIPK1 Q13546 1/20 0.51
IDO1 P14902 2/20 0.45
THRB P10828 1/20 0.45
MAPT P10636 3/20 0.43
KDM4E B2RXH2 1/20 0.43
CYP3A4 P08684 1/20 0.43
MEN1 O00255 4/20 0.42
KMT2A Q03164 4/20 0.42
ALDH1A1 P00352 2/20 0.41
RAB9A P51151 2/20 0.41
LMNA P02545 2/20 0.41
ALOX12 P18054 3/20 0.41
HPGD P15428 2/20 0.41
SMN1; SMN2 Q16637 2/20 0.41
GAA P10253 2/20 0.41
ALPL P05186 1/20 0.41
HTT P42858 1/20 0.41
TDP1 Q9NUW8 1/20 0.40
ATM Q13315 1/20 0.40
POLB P06746 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5431000 0.81 IDO1 (0.50) RIPK1IDO1THRBMAPTKDM4E
SCHEMBL4154636 0.81 IDO1 (0.50) RIPK1IDO1THRBMAPTKDM4E
SCHEMBL9482260 0.81 IDO1 (0.61) IDO1THRBMAPTKDM4ECYP3A4
SCHEMBL20686991 0.79 RIPK1 (0.50) RIPK1IDO1THRBMAPTKDM4E
SCHEMBL6891746 0.79 RIPK1 (0.50) RIPK1IDO1THRBMAPTKDM4E
SCHEMBL11597027 0.79 EPHX2 (0.49) RIPK1MEN1KMT2ASMN1; SMN2GAA
SCHEMBL11677767 0.78 ATM (0.56) RIPK1IDO1THRBMAPTKDM4E
SCHEMBL20163215 0.78 RIPK1 (0.49) RIPK1IDO1THRBMAPTKDM4E
SCHEMBL10703980 0.78 RAB9A (0.50) RIPK1IDO1THRBMAPTKDM4E
SCHEMBL10949413 0.78 SLC6A2 (0.48) RIPK1IDO1THRBMAPTKDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-5945345-A TRANSPORT MATRIX FOR PHYSIOLOGICAL FLUID IMMUNOASSAY COMPRISED OF SAMPLE RECEPTACLE ZONE, DETECTION ZONE, AND INSOLUBLE ACTIVE CHEMICAL ELEMENT TO BIND AND IMMOBILIZE INTERFERING SUBSTANCES METRIKA, INC. (US) 1999-08-31 US claimed
WO-1998009167-A1 DEVICE AND METHOD FOR PREVENTING ASSAY INTERFERENCE METRIKA, INC. (US) 1998-03-05 WO claimed
JP-60031829-A None JP disclosed
CN-109125714-B A method for purifying therapeutic proteins 德国杰特贝林生物制品有限公司 2022-08-02 CN disclosed
CN-109689124-B Liver support system 甘布罗伦迪亚股份公司 2021-12-03 CN disclosed
CN-102186812-A Methods for preparing fluoroalkyl arylsulfinyl compounds and fluorinated compounds thereto UBE INDUSTRIES 2011-09-14 CN disclosed
US-20110190511-A1 Methods For Preparing Fluoroalkyl Arylsulfinyl Compounds And Fluorinated Compounds Thereto IM&T RESEARCH, INC. (US) 2011-08-04 US disclosed
EP-2323974-A1 METHODS FOR PREPARING FLUOROALKYL ARYLSULFINYL COMPOUNDS AND FLUORINATED COMPOUNDS THERETO Ube Industries, Ltd. (JP) 2011-05-25 EP disclosed
US-20100152463-A1 Methods for Preparing Fluoroalkyl Arylsulfinyl Compounds and Fluorinated Compounds Thereto IM&T RESEARCH, INC. (US) 2010-06-17 US disclosed
WO-2010022001-A1 METHODS FOR PREPARING FLUOROALKYL ARYLSULFINYL COMPOUNDS AND FLUORINATED COMPOUNDS THERETO IM&T RESEARCH, INC. (US) 2010-02-25 WO disclosed
EP-1509196-A1 SELECTIVE REMOVAL OF CONTAMINANTS FROM A SURFACE USING COLORED MAGNETIC PARTICLES AND ARTICLES HAVING MAGNETS Kimberly-Clark Worldwide, Inc. (US) 2005-03-02 EP disclosed
WO-2001028511-A9 SELECTIVE REMOVAL OF CONTAMINANTS FROM A SURFACE USING MAGNETS KIMBERLY CLARK CO (US) 2002-11-21 WO disclosed
WO-2001028512-A9 SELECTIVE REMOVAL OF CONTAMINANTS FROM A SURFACE USING ARTICLES HAVING MAGNETS KIMBERLY CLARK CO (US) 2002-08-08 WO disclosed
EP-1114143-A1 STREPTOCOCCAL C BETA PROTEIN COMPOSITIONS NORTH AMERICAN VACCINE, INC. (CA) 2001-07-11 EP disclosed
WO-2001028511-A2 SELECTIVE REMOVAL OF CONTAMINANTS FROM A SURFACE USING MAGNETS KIMBERLY-CLARK WORLDWIDE, INC. (US) 2001-04-26 WO disclosed
WO-2001028512-A1 SELECTIVE REMOVAL OF CONTAMINANTS FROM A SURFACE USING ARTICLES HAVING MAGNETS KIMBERLY-CLARK WORLDWIDE, INC. (US) 2001-04-26 WO disclosed
WO-2000015760-A1 STREPTOCOCCAL C BETA PROTEIN COMPOSITIONS NORTH AMERICAN VACCINE, INC. (US) 2000-03-23 WO disclosed
US-5945345-A TRANSPORT MATRIX FOR PHYSIOLOGICAL FLUID IMMUNOASSAY COMPRISED OF SAMPLE RECEPTACLE ZONE, DETECTION ZONE, AND INSOLUBLE ACTIVE CHEMICAL ELEMENT TO BIND AND IMMOBILIZE INTERFERING SUBSTANCES METRIKA, INC. (US) 1999-08-31 US disclosed
WO-1998009167-A1 DEVICE AND METHOD FOR PREVENTING ASSAY INTERFERENCE METRIKA, INC. (US) 1998-03-05 WO disclosed
JP-S6031829-A HIGH PURITY REFINING METHOD OF AQUEOUS NON-ELECTROLYTIC ORGANIC SUBSTANCE SOLUTION DOW CHEM NIPPON KK 1985-02-18 JP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100152463-A1 Methods for Preparing Fluoroalkyl Arylsulfinyl Compounds and Fluorinated Compounds Thereto PFAS, AGPS, FDPS RIPK1 4874/4885IDO1 2030/4885THRB 2510/4885
US-20110190511-A1 Methods For Preparing Fluoroalkyl Arylsulfinyl Compounds And Fluorinated Compounds Thereto PFAS, AGPS, FDPS RIPK1 4868/4885IDO1 1620/4885THRB 2429/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.